Daniel Garcia

Daniel’s practice focuses on advising US and international biotechnology and pharmaceutical companies on commercial and operational agreements across the full product life cycle. He regularly counsels clients on research collaboration agreements, material transfer agreements, licensing arrangements, clinical trial agreements, investigator-initiated trial agreements, and master services agreements with Contract Research Organizations and other strategic service providers—including consulting and scientific advisory contracts. His experience also extends to manufacturing services agreements for both clinical and commercial supply, along with other key arrangements that support product development and distribution. Trained in both civil and common law jurisdictions, Daniel brings a distinct international perspective to his practice, enabling him to bridge legal and cultural gaps and deliver cohesive, strategic solutions in cross-border commercial contracting.

• AlloVir, Inc. in the review and negotiation of multiple operational and commercial contracts relevant for its studies conducted in the United States, Europe, and Asia, including clinical trial agreements, research collaboration agreements, licensing agreements, master services agreements with contract research organizations, and manufacturing services agreements for clinical supply;
• A publicly traded immuno-oncology company in the review and negotiation of manufacturing services agreements for both clinical and commercial supply of its cancer-focused therapeutic product.
• A clinical-stage biopharmaceutical company focused on therapies for serious liver diseases in the negotiation of various operational and commercial agreements, including manufacturing services agreements, research collaboration agreements, consulting agreements, scientific advisory agreements, and agreements with contract research organizations.
• An AI-based medical imaging company focused on cardiovascular diagnostics in the review and negotiation of research collaboration agreements, clinical trial agreements, and master services agreements with CROs for studies conducted in the US and internationally.
• Bellicum Pharmaceuticals, a clinical-stage biopharmaceutical company in connection with the sale of its biomanufacturing facility.
• A clinical-stage biopharmaceutical company developing therapies for central nervous system cancers in the negotiation of various pre-clinical and clinical research and collaboration agreements, as well as master services agreements with CROs for studies conducted in the US and internationally.
• A global health-focused nonprofit organization in the negotiation of agreements with CROs for multi-country studies, coordinating closely with subject matter experts and local counsel across jurisdictions.
• Immatics US Inc. and Immatics Biotechnologies GmbH in the drafting and negotiation of a wide range of operational and strategic agreements, including material transfer agreements, clinical trial agreements, research collaboration agreements, licensing arrangements, and manufacturing and supply agreements supporting the development of their immunotherapies.
• ImmunoGenesis, Inc. in the negotiation of key commercial and development agreements supporting its immuno-oncology pipeline, including clinical trial agreements, research collaboration arrangements, consulting and advisory contracts, and manufacturing services agreements for its lead therapeutic candidates.
• March Biosciences, Inc. in the review and negotiation of manufacturing and development services agreements to support the production of its CAR-T cell therapy candidates, including arrangements for clinical supply and related operational support.
• A US-based research reactor facility affiliated with a public university in the negotiation of service agreements for the irradiation of materials used in the development of radiopharmaceuticals for cancer and other medical applications.
• Plus Therapeutics, Inc., a clinical-stage pharmaceutical company developing targeted radiotherapeutics for rare and difficult-to-treat cancers, in the negotiation of key clinical and development agreements, including clinical trial agreements and consulting arrangements aligned with its radiopharmaceutical pipeline. 
• A radiopharmaceutical company focused on advancing cancer treatments through targeted radiation and imaging technologies in the drafting and negotiation of strategic and operational agreements, including research collaboration agreements and development services contracts, to support the delivery of precision therapies directly to tumor sites.

• State Bar of Texas - Member
• The Florida Bar - Member
• The District of Columbia Bar - Member
• American Bar Association - Member